Sarcopenic obesity in patients with arterial hypertension and metabolic dysfunction-associated steatotic liver disease. Part 2

Aim. The purpose of the study was to evaluate the nonspecific inflammatory markers and study their impact on cardiometabolic risk in patients with arterial hypertension (AH) and metabolic dysfunction-associated steatotic liver disease (MASLD) depending on the presence of sarcopenic obesity.

Materials and methods. This article is a continuation of the article “Sarcopenic obesity in patients with arterial hypertension and metabolic dysfunction-associated steatotic liver disease: focus on inflammation. Part 1” [12]. The second part of the article presents data on the influence of inflammatory markers and proinflammatory cytokines on cardiometabolic risks in patients with sarcopenic obesity, AH and MASLD.

Results. A total of 133 patients with AH and MASLD were included in the study during the recruitment period. Women accounted for 43.6% (n = 58). The mean age of the subjects was 48.0±7.99 years, and the median duration of hypertension was 8.0 (3.0–14.5) years. Patients with sarcopenic obesity had higher values of nonspecific inflammatory markers. This group also had higher blood pressure, liver elasticity, and FLI values. Correlation analysis revealed numerous associations between inflammatory markers, cardiometabolic risks, body composition, muscle strength, and functional indicators in patients with AH and MASLD.

Conclusion. The muscle-to-fat ratio in obese patients, as well as decreased muscle strength and impaired muscle function, may be associated with altered serum concentrations of nonspecific inflammatory markers, suggesting the role of proinflammatory cytokines in both the development and progression of sarcopenic obesity. Specifically, addressing chronic inflammation is considered a key mechanism for treating sarcopenic obesity, atherosclerosis, MASLD, and AH. The study and clinical implementation of therapeutic and preventive measures aimed at preserving muscle mass and strength and minimizing the impact of sarcopenia on the risk of cardiovascular disease in adults with AH and fatty liver disease are among the top priority areas of healthcare.

1. Sarcopenia: revised European consensus on definition and diagnosis / A.J. Cruz-Jentoft [et al.] // Age Ageing. – 2019. – Vol. 48, №. 1. – Р. 16–31. doi: 10.1093/ageing/afy169

2. Индекс саркопении для выявления сниженной мышечной силы и массы у пациентов с неалкогольной жировой болезнью печени / А.Ф. Шептулина [и др.] // Профилактическая медицина. – 2025. – Т 28, № 7. – С. 68–74. doi:10.17116/profmed20252807168

3. Sarkopeniya i perekrestnye sindromy – znachenie v klinicheskoj praktike [Sarcopenia and cross syndromes – significance in clinical practice] / N.A. Shostak [et al.] // Klinicist. – 2016. – Vol. 10, № 3. – Р. 10–14. doi:10.17650/1818-8338-2016-10-3-10-14. (in Russian).

4. Клинические последствия саркопенического ожирения. Часть 1. Неалкогольная жировая болезнь печени, сахарный диабет 2-го типа, хроническая болезнь почек / А.Ф. Шептулина [и др.] // Профилактическая медицина. – 2024. – T. 27, № 8. – Р. 114–120. doi:10.17116/profmed202427081114

5. Лабораторные маркеры остеосаркопенического ожирения / О.В. Гриценко [и др.] // Российский кардиологический журнал. – 2023. – Т. 28, № 12. – С. 133–141. doi:10.15829/1560-4071-2023-5563.

6. Ассоциация саркопении иатеросклероза сонных артерий убольных мужского пола пожилого возраста состеоартритом коленного сустава / Л.И. Алексеева [и др.] // РМЖ. Медицинское обозрение. – 2022. – Vol. 6, № 3. – Р. 120–125. doi: 10.32364/2587-6821-2022-6-3-120-125.

7. A multi-society Delphi consensus statement on new fatty liver disease nomenclature / M.E. Rinella [et al.] // Hepatology. – 2023. doi: 10.1097/HEP.0000000000000520.

8. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement / L.M. Donini [et al.] // Obes Facts. – 2022. – Vol. 15, № 3. – Р. 321-335. doi: 10.1159/000521241

9. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People / A.J. Cruz-Jentoft [et al.] // Age Ageing. – 2010– Vol. 39, № 4. – P. 412-23. doi.org/10.1093/ageing/afq034.

10. Short Physical Performance Battery as a Measure of Physical Performance and Mortality Predictor in Older Adults: A Comprehensive Literature Review / de Fátima Ribeiro Silva C[et al.] // Int J Environ Res Public Health. – 2021. – Vol. 18, № 20. – P. 10612. doi: 10.3390/ijerph182010612.

11. Саркопения и саркопеническое ожирение: современные возможности диагностики и лечения: учеб.-метод. пособие. / М.В. Штонда, [и др.]. – Минск : БелМАПО, 2023. – 28 с.

12. Саркопеническое ожирение у пациентов с артериальной гипертензией и метаболически ассоциированной жировой болезнью печени: фокус на воспаление. Часть 1 / К.Ю. Антюх [и др.] // Неотложная кардиология и кардиоваскулярные риски. – 2025. – Т. 9, № 1. – С. 2390-2403. doi:10.51922/2616-633X.2025.9.1.2390

13. Sarcopenia Is Associated with High Pulse Pressure in Older Women / H.J. Coelho Júnior [et al.] // J Aging Res. – 2015. - Vol. 2015. – Р. 1-6. doi: 10.1155/2015/109824

14. A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors / К. Sanada [et al.] // Eur J Appl Physiol. – 2010. – Vol. 110, № 1. – Р. 57–65. doi: 10.1007/s00421-010-1473-z.

15. Sarcopenia, sarcopenic obesity, and arterial stiffness among older adults / F. Fantin [et al.] // Front Cardiovasc Med. – 2024. – Vol. 11. – Р. 1–8. doi:10.3389/fcvm.2024.1272854.

16. Meng, D. C-reactive protein and frailty in the elderly: a literature review / D.Meng, N.Pantzaris, I. Koniari // J. Clin. Med. – 2017. – Vol. 9. – P. 461-465. doi: 10.14740/jocmr2959w

17. Sarcopenia and Cardiovascular Diseases / А.А. Damluji [et al.] // Circulation. – 2023. – Vol. 147, № 20. – Р. 1534–1553. doi: 10.1161/CIRCULATIONAHA.123.064071.

18. Остеосаркопеническое ожирение у пациентов с сердечно-сосудистыми заболеваниями. Спорные и нерешенные вопросы / К.Е. Кривошапова [и др.] // Кардиоваскулярная терапия и профилактика. – 2021. – Т. 20, № 6. – С. 2787. doi:10.15829/1728880020212787

19. Causal associations of sarcopenia-related traits with cardiometabolic disease and Alzheimer’s disease and the mediating role of insulin resistance: A Mendelian randomization study / Ye C Kong L [et al.] // Aging Cell. – 2023. – Vol. 22, № 9. – С. 1–14. doi: 10.1111/acel.13923.